首页 文献索引 SCI期刊 AI助手
期刊目录筛选

期刊名:Alzheimers & dementia-translational research & clinical interventions

缩写:

ISSN:N/A

e-ISSN:2352-8737

IF/分区:6.8/Q1

文章目录 更多期刊信息

共收录本刊相关文章索引1029
Clinical Trial Case Reports Meta-Analysis RCT Review Systematic Review
Classical Article Case Reports Clinical Study Clinical Trial Clinical Trial Protocol Comment Comparative Study Editorial Guideline Letter Meta-Analysis Multicenter Study Observational Study Randomized Controlled Trial Review Systematic Review
Maurizio Giorelli Maurizio Giorelli
Alzheimer's disease (AD) is the leading cause of dementia, but simple models focusing on amyloid beta and tau only partially explain its variability and limited success in treatment. Evidence from systems biology, neuroimmunology, connectom...
Avijit Podder,Yi Juin Liew,Gregory A Cary et al. Avijit Podder et al.
Introduction: Alzheimer's disease (AD) exhibits considerable inter-individual variability in clinical presentation, neuropathological burden, and underlying molecular processes. Conventional cohort-based analyses of omics...
José María García-Alberca,Silvia Mendoza,Paz DE LA Guía et al. José María García-Alberca et al.
Introduction: The burden experienced by caregivers of Alzheimer´s disease (AD) patients is a complex and stressful situation influenced by distinct variables, such as the patient´s need for monitoring, social isolation,...
Susanna Gobbi,Erica Silvestri,Matteo Tonietto et al. Susanna Gobbi et al.
Introduction: Alzheimer's disease (AD) heterogeneity poses significant challenges for drug development, identification of individuals at risk, and treatment response prediction. Scientists have leveraged graph theory and ...
Ying Xu,Perminder S Sachdev,Matthew J Lennon Ying Xu
Introduction: There are currently no approved medicines for vascular cognitive impairment and dementia (VCID). Methods: We reviewed cli...
Jeffrey L Cummings,Yadi Zhou,Yuxin Yang et al. Jeffrey L Cummings et al.
Introduction: Discovery and development of new therapies for Alzheimer's disease (AD) are urgently needed to address the world's growing population of individuals on the AD pathophysiological continuum. Clinicaltrials.gov...
Mona Darwish,Nancy Lin,Bryan Dirks et al. Mona Darwish et al.
Introduction: Remlifanserin, or ACP-204, is a potent serotonin 2A receptor inverse agonist under investigation for treatment of Alzheimer's disease psychosis and Lewy body dementia psychosis. A population pharmacokinetics...
David Lukacsovich,Juan I Young,Lissette Gomez et al. David Lukacsovich et al.
Introduction: Cognitive reserve (CR) reflects variability in cognitive adaptability that modifies the impact of Alzheimer's disease (AD) pathology on cognition. However, blood-based biomarkers of CR have not been establis...
Peace Esther Johnson,Roxanne Vandermause Peace Esther Johnson
It is crucial to identify practices that effectively meet the unique spiritual needs of Black persons living with dementia. Currently, ≈ 7 million individuals in the United States are affected by dementia, a figure that is expected to rise...
Matthew J Lennon,Ying Xu,Anbupalam Thalamuthu et al. Matthew J Lennon et al.
Background: There are currently no US Food and Drug Administration-approved treatments for vascular dementia (VaD). Genome-wide approaches have successfully identified druggable targets and treatments for various disorder...